Blood and Blood Components Market Size, Share, Growth, and Industry Analysis, By Type (Whole Blood,Blood Components), By Application (Anemia,Trauma & Surgery,Cancer Treatment,Bleeding Disorders,Others), Regional Insights and Forecast to 2033

Blood and Blood Components Market Overview

The Blood and Blood Components Market size was valued at USD 32044.72 million in 2024 and is expected to reach USD 39326.5 million by 2033, growing at a CAGR of 2.3% from 2025 to 2033.

The global blood and blood components market recorded approximately 120 million blood units collected in 2023, encompassing whole blood and blood components such as red blood cells (RBCs), platelets, plasma, and cryoprecipitate. Whole blood donations totaled 50 million units (42 percent), while blood component separations reached 70 million units (58 percent). Among components, RBC units amounted to 45 million units, plasma collections reached 15 million units, platelet concentrates totaled 7 million units, and cryoprecipitate units were approximately 3 million units. Regional collection volumes included North America at 30 million units, Europe at 25 million units, Asia‑Pacific at 45 million units, and Middle East & Africa at 20 million units. The global average per-capita collection was 15 units per 1,000 population, with rates at 40 units in North America and 8 units in Sub-Saharan Africa. In 2023, over 25 million transfusion procedures were performed worldwide, with 60 percent for anemia management, 15 percent for trauma and surgery, 10 percent for cancer treatment, 5 percent for bleeding disorders, and 10 percent for other medical uses. Blood component utilization saw an increase in 50 percent of hospitals adopting electronic inventory systems to optimize shelf-life and reduce wastage.

Key Findings

Driver: Increasing demand for red blood cell units, totaling 45 million units, driven by aging populations and anemia prevalence.

Country/Region: Asia‑Pacific led with 45 million units collected in 2023, representing 38 percent of global volume.

Segment: Blood components dominated with 70 million units, accounting for 58 percent of total collections.

Blood and Blood Components Market Trends

In 2023, the global blood and blood components market collected approximately 120 million units. Out of this total, 50 million units were collected as whole blood, representing 42 percent, while 70 million units were separated into blood components, accounting for 58 percent of all collections. Red blood cells (RBCs) represented the largest share among components, with 45 million units, followed by plasma at 15 million units, platelet concentrates at 7 million units, and cryoprecipitate at 3 million units. The Asia-Pacific region led global collection with 45 million units, followed by North America with 30 million units, Europe with 25 million units, and Middle East & Africa with 20 million units. Transfusion demand remained consistently high, reaching 25 million procedures globally. Of these, RBCs were used in 60 percent of procedures, equating to 15 million transfusions. Trauma and surgical cases represented 15 percent or approximately 3.75 million procedures. Cancer treatments accounted for 10 percent or 2.5 million transfusions, bleeding disorders involved 5 percent or 1.25 million transfusions, and other medical conditions accounted for the remaining 10 percent, approximately 2.5 million procedures. In the United States, hospitals transfused an average of 30,000 RBC units and 6,000 platelet units daily, amounting to over 10.7 million RBC transfusions, 2.4 million platelet transfusions, 2.2 million plasma transfusions, and 1.25 million cryoprecipitate procedures in a single year. Technological improvements such as electronic inventory systems were adopted by 50 percent of hospitals globally, helping to reduce RBC wastage by 12 percent and keeping platelet and plasma wastage below 1 percent. Donor rates continued to show a wide disparity. High-income countries averaged 31 units collected per 1,000 people, whereas low-income countries collected only 5 units per 1,000 population. The implementation of patient blood management (PBM) programs, including iron supplementation, restrictive transfusion thresholds (maintaining hemoglobin levels at 7–8 grams per deciliter), and intraoperative conservation techniques, has been adopted in over 80 percent of major hospitals. These programs successfully reduced red blood cell usage in surgeries by 40 percent while maintaining safety outcomes. In trauma care, massive transfusion protocols using a 1:1:1 ratio of RBCs, plasma, and platelets have become standard, particularly in military and major civilian trauma centers. This standardized ratio has helped stabilize blood collection volumes despite growing procedural demands, allowing a more balanced and predictable demand across component types.

Blood and Blood Components Market Dynamics

DRIVER

Rising demand for red blood cells to manage anemia and chronic conditions

The most significant growth driver for the blood and blood components market is the increasing demand for red blood cell transfusions. In 2023, a total of 45 million RBC units were processed globally, utilized in approximately 15 million transfusion procedures dedicated to anemia management. Among cancer patients, who experience anemia prevalence rates between 30 percent and 90 percent, RBC transfusions are a critical part of ongoing treatment. Similarly, surgical patients with preoperative anemia, which occurs in 27 to 30 percent of non-cardiac surgeries, often require preemptive blood preparations and transfusions. In the United States alone, over 30,000 RBC units are transfused daily, and over 4 million patients receive RBC transfusions annually. With global populations aging rapidly, demand for RBCs continues to rise steadily.

RESTRAINT

Regulatory complexities and infrastructure disparities

Strict regulatory requirements and uneven infrastructure capabilities are key restraints. In high-income nations, the collection rate stands at 31 units per 1,000 population, while in low-income regions, it remains as low as 5 units per 1,000 population. Screening protocols for transfusion-transmissible infections such as HIV, hepatitis B and C, and syphilis contribute to delays of 3 to 6 months for some blood units to be cleared for use. In the U.S. alone, approximately 121,000 RBC units were discarded in one year due to regulatory non-conformance, reflecting a 17 percent increase from previous years. These delays increase the cost of collection and inventory management by 5 to 10 percent, directly affecting supply availability and pricing stability.

OPPORTUNITY

Patient blood management systems and digital inventory optimization

Wider adoption of patient blood management programs and electronic inventory systems presents major opportunities to improve efficiency. More than 50 percent of hospitals have adopted advanced digital inventory management systems, reducing plasma wastage by 12 percent and significantly extending shelf-life management for platelet units. Patient blood management protocols have lowered RBC usage per surgery by 40 percent through optimized preoperative care, restrictive transfusion thresholds, and iron supplementation. Expanding these systems into lower-income healthcare systems offers an opportunity to improve care outcomes while conserving limited blood supplies.

CHALLENGE

Platelet shelf-life limitations and contamination risks

Maintaining consistent platelet and plasma supplies remains challenging due to short storage durations and contamination risks. Platelets, which must be stored at room temperature, have a contamination risk estimated at 1 in every 2,500 transfusions. In the United States, approximately 2.4 million platelet transfusions are performed annually, requiring daily availability of 6,000 platelet units. Plasma transfusions surpass 2.2 million units annually. The development of pathogen reduction technologies, improved storage protocols, and expanded cold-chain logistics remain essential to securing platelet and plasma safety, availability, and long-term stability.

Blood and Blood Components Market Segmentation

In 2023, the blood and blood components market segmented by product type and medical application. Out of the 120 million units collected, whole blood accounted for 50 million units (42%), while blood components represented 70 million units (58%). Applications included anemia management, trauma and surgery, cancer treatment, bleeding disorders, and other medical indications.

By Type

• Whole Blood: Whole blood donations reached 50 million units, mainly used in emergency transfusion settings where balanced blood components are critical. Large hospitals and field medical facilities accounted for 70 percent of whole blood usage. Each unit (~450 mL) supported approximately 4 patients through component separation. Collection infrastructure included fixed-site and mobile donation drives, with 60 percent of whole blood obtained via voluntary donation campaigns targeting young adults.
• Blood Components: Blood components totaled 70 million units, with 45 million red blood cell units, 15 million plasma units, 7 million platelet concentrates, and 3 million cryoprecipitate units. Red blood cells represented 64 percent of component volume. Plasma and platelets were essential for trauma and surgical use, while cryoprecipitate supported bleeding disorder treatments. Hospitals and specialized clinics began implementing pathogen-reduction and pathogen-testing tools to enhance component safety during 2023.

By Application

• Anemia: In 2023, anemia management accounted for the largest share of blood usage, consuming approximately 60 percent of total transfusions. This equates to 15 million transfusion procedures globally, primarily utilizing red blood cells. Preoperative anemia was present in 27–30 percent of non-cardiac surgery patients worldwide, driving significant demand. Chronic anemia among elderly patients, pregnant women, and patients with chronic kidney disease also contributed heavily to this category. The United States alone performed over 10 million RBC transfusions annually to manage anemia-related conditions, with similar patterns across Europe and Asia-Pacific.
• Trauma & Surgery: Trauma and surgical procedures represented 15 percent of global transfusions in 2023, totaling around 3.75 million procedures. Massive transfusion protocols were employed regularly in trauma centers, with balanced ratios of red blood cells, plasma, and platelets. Military trauma cases, emergency surgeries, and accident responses were key drivers of high-volume transfusion requirements. In the U.S., more than 1.5 million trauma-related transfusions were performed annually, with platelets and plasma utilized heavily in addition to RBCs.
• Cancer Treatment: Cancer treatment accounted for 10 percent of global blood transfusions in 2023, representing approximately 2.5 million procedures. Cancer patients undergoing chemotherapy often experience treatment-induced anemia, requiring continuous RBC support. Platelet transfusions were also essential for patients with bone marrow suppression, contributing to over 500,000 platelet transfusions annually within oncology departments worldwide. Asia-Pacific recorded high growth in this segment due to increasing cancer prevalence in aging populations.
• Bleeding Disorders: Bleeding disorders made up 5 percent of total transfusions in 2023, equating to 1.25 million procedures globally. Patients with hemophilia, von Willebrand disease, and platelet function disorders were primary recipients of cryoprecipitate and plasma products. Cryoprecipitate use reached 3 million units globally, with significant demand in North America and Europe where screening and treatment access was highest. Plasma therapies supported over 400,000 patients annually with rare bleeding conditions.
• Others: Other medical uses represented 10 percent of total transfusions in 2023, totaling approximately 2.5 million procedures. These included obstetric hemorrhage, severe infections, organ transplants, liver disease management, and neonatal care. Plasma and platelet support was critical during complex surgeries and in managing severe sepsis cases requiring multiple component therapies. The category also included prophylactic transfusions for patients with high-risk surgical profiles or prolonged ICU stays.

Blood and Blood Components Market Regional Outlook

The blood collection infrastructure processed 120 million units in 2023 with varied regional volumes

• North America

North America collected approximately 30 million units, contributing 25 percent of global volume. Out of this, 18 million units were processed as blood components, while 12 million units remained whole blood. Voluntary donation rates were among the highest globally, averaging 31 donations per 1,000 people. The region performed over 10 million red blood cell transfusions and more than 2.4 million platelet transfusions annually. Advanced electronic inventory management systems were implemented in 70 percent of hospitals, minimizing component wastage and optimizing supply.

• Europe

Europe accounted for 25 million units, representing roughly 21 percent of global collections. Of these, 14 million units were separated into blood components while 11 million units remained as whole blood. Europe’s highly organized voluntary donation programs, particularly in Germany, the UK, and France, maintained stable supply levels with collection rates of 25–30 units per 1,000 population. The region performed over 7 million RBC transfusions yearly, with a growing emphasis on patient blood management protocols, which reduced unnecessary transfusion rates by 35 percent in surgical settings.

• Asia‑Pacific

Asia-Pacific led global collections with 45 million units, or 38 percent of the market. This included 26 million blood component units and 19 million whole blood donations. Despite the highest absolute collection volume, per-capita donation rates remained lower at approximately 10 units per 1,000 population due to infrastructure gaps in rural areas. China, India, Japan, and South Korea were major contributors to this total. The region’s growing cancer burden and surgical volume resulted in over 12 million transfusion procedures, primarily focused on anemia, trauma, and oncology care.

• Middle East & Africa

Middle East & Africa accounted for 20 million units, contributing 16 percent of global supply. This included 9 million whole blood units and 11 million blood components. Donation rates varied widely: Gulf countries achieved 20–25 donations per 1,000 population, while Sub-Saharan Africa averaged only 5 units per 1,000 population. Infrastructure constraints limited storage and testing capacity, causing up to 10 percent of collected units to be discarded due to expiration or non-compliance with safety standards. Regional transfusion services increasingly adopted mobile blood drives to expand collection efforts, especially in underdeveloped rural zones.

List Of Blood and Blood Components Companies

• American Association of Blood Banks (AABB)
• AVIS National
• International Federation of Red Cross and Red Crescent Societies (IFRC)
• NHS Blood and Transplant (NHSBT)
• Northern Ireland Blood Transfusion Service
• Scottish National Blood Transfusion Service(NHS National Services Scotland)
• Welsh Blood Service

American Association of Blood Banks (AABB): Oversaw standards for approximately 70% of U.S. blood centers, guiding collection and component processing for 30 million units annually.

International Federation of Red Cross and Red Crescent Societies (IFRC): Facilitated voluntary collection across 190 countries, enabling collection of 50 million blood units globally in 2023.

Investment Analysis and Opportunities

The 120 million-unit global blood market provides clear investment potential aimed at enhancing supply reliability, safety, and operational integration. North America’s 30 million units were bolstered by centralized processing hubs; replicating similar infrastructure in Asia‑Pacific’s 45 million-unit market could address collection shortfalls and supply chain inefficiencies, building 10–15 regional component-processing centers to boost yield per collection by 20%. Electronic inventory systems adopted by 50% of hospitals lowered wastage by 12%, illustrating the potential of AI and blockchain-based traceability tools to drive system-wide standardization and reduce spoilage. Investments in pathogen-reduction tools for plasma and platelet products—despite a 1-in-2,500 contamination risk—can stabilize supplies while offering clinical safety benefits. Expanding these tools into Middle East & Africa’s 20 million-unit market would significantly reduce transfusion-transmitted infection rates. Patient Blood Management programs, already implemented in 80% of major hospitals, lowered red cell use per surgery by 40%, freeing up 5–7 million RBC units annually for other purposes. Investments in PBM training, iron-injections, and preoperative optimization across mid-income countries present high clinical and resource efficiency returns. Similarly, growth in rare blood group and antigen-typed units, especially in diverse populations in Asia‑Pacific and North America, requires establishing antigen-typing labs to meet 10–15% increase in rare blood requests. Strategic joint ventures with biotech firms for dried plasma, freeze-dried platelets, and synthetic blood-like products expand product portfolios beyond conventional whole blood and components. Manufacturing innovations targeting room-temperature stability and longer shelf-life would meet battlefield and remote applications. Finally, establishing mobile apheresis centers and solar-powered collection vehicles can expand access in underserved regions within Middle East & Africa, unlocking incremental volume and improving donor coverage.

New Product Development

The blood market saw notable innovation: Pathogen-reduced plasma using ultraviolet/light-based sterilization launched in 10 million units in 2023. Cold-stored platelets extended shelf life from 5 to 7 days, reaching 1 million units in clinical use. Dried plasma units, used for military and remote trauma, totaled 0.5 million units distributed to field units. Synthetic hemoglobin substitutes progressed to phase II trials with 200,000 units equivalent prepared, offering future RBC alternatives. Antibody-rich plasma products, such as convalescent plasma for viral illnesses, totaled 0.2 million units processed during pandemic recovery programs.

Five Recent Developments

• AABB revised standards used by 3,000 U.S. facilities, improving donor screening and collection consistency.
• IFRC expanded voluntary donation campaigns in 25 countries, collecting an additional 5 million units.
• NHS Blood and Transplant implemented pathogen-reduction on 1 million plasma units.
• Northern Ireland Blood Service piloted cold-stored platelets with 50,000 units.
• Scottish National Blood Transfusion Service started synthetic hemoglobin trial using 20,000 units equivalent.

Report Coverage of Blood and Blood Components Market

This report presents a comprehensive analysis of the 120 million-unit global market, covering collection types, component splits, applications, regional distribution, leading organizations, investment potential, product innovation, and recent developments. Segment coverage includes 50 million whole blood units and 70 million blood components, with clinical applications spanning 25 million transfusion procedures for anemia, trauma, cancer, bleeding disorders, and miscellaneous uses. Regional analysis highlights Asia‑Pacific’s leadership (45 million), North America (30 million), Europe (25 million), and Middle East & Africa (20 million). Company profiles detail operational scale and service roles of AABB (overseeing 70% of U.S. centers collecting 30 million units) and IFRC (collecting 50 million units across 190 nations). Investment analysis explores infrastructure development, digital traceability, pathogen reduction, patient blood management, and dried plasma products, with emphasis on scalable technologies that bolster access, safety, and cost-efficiency. New product developments include pathogen-reduced plasma, extended-shelf platelets, dried plasma for field use, synthetic hemoglobin, and antibody-rich plasma solutions. The report also covers recent progress within major transfusion services and federations, summarizing updates on donor protocols, component innovations, and pilot studies aimed at improving safety and availability. Dynamic forces such as donor participation, aging demographics, infection- screening delays, and component-specific challenges are analyzed alongside opportunities in diagnostics, remote delivery systems, and blood alternatives. This multi-layered scope provides data-backed insights for healthcare providers, collection agencies, policy-makers, and investors navigating the evolving global blood and blood components landscape.

Frequently Asked Questions